Susquehanna International Group, LLP Cabaletta Bio, Inc. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$3.94 - $8.24 $343,174 - $717,704	87,100 New	87,100 $411,000
Q1 2024 May 07, 2024	SELL	$16.79 - $25.38 $703,501 - $1.06 Million	-41,900 Reduced 25.15%	124,700 $2.13 Million
Q4 2023 Feb 14, 2024	BUY	$12.21 - $23.36 $1.42 Million - $2.72 Million	116,400 Added 231.87%	166,600 $3.78 Million
Q3 2023 Nov 14, 2023	SELL	$11.84 - $18.65 $413,216 - $650,885	-34,900 Reduced 41.01%	50,200 $764,000
Q2 2023 Aug 11, 2023	BUY	$7.65 - $13.95 $384,030 - $700,290	50,200 Added 143.84%	85,100 $1.1 Million
Q1 2023 May 16, 2023	BUY	$7.08 - $12.62 $2,124 - $3,785	300 Added 0.87%	34,900 $288,000
Q4 2022 Feb 14, 2023	SELL	$0.64 - $9.3 $13,440 - $195,300	-21,000 Reduced 37.77%	34,600 $320,000
Q3 2022 Nov 14, 2022	BUY	$0.63 - $2.05 $35,028 - $113,979	55,600 New	55,600 $36,000
Q4 2021 Feb 14, 2022	SELL	$3.36 - $14.64 $98,784 - $430,416	-29,400 Reduced 49.83%	29,600 $112,000
Q3 2021 Nov 15, 2021	BUY	$7.0 - $12.5 $413,000 - $737,500	59,000 New	59,000 $717,000

126

47.9M

202K

110K

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $66.4M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.